Functional diarrhea

Current Gastroenterology Reports

Volumn 7, Issue 5, 2005, Pages 350-357

  Farthing, Michael J G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; CHINESE DRUG; CILANSETRON; HERBACEOUS AGENT; PREDNISOLONE; PROBIOTIC AGENT; SEROTONIN; SEROTONIN ANTAGONIST;

ABDOMINAL PAIN; BACTERIAL FLORA; BACTERIAL OVERGROWTH; BEHAVIOR THERAPY; BIFIDOBACTERIUM; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DEFECATION; DIARRHEA; DISEASE ASSOCIATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPNOSIS; INFLAMMATION; INTESTINE INFECTION; IRRITABLE COLON; ISCHEMIC COLITIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PSYCHOTHERAPY; REVIEW;

EID: 28244468601     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-005-0003-3     Document Type: Review

References (61)

1. Thompson WG, Creed F, Drossman DA, et al.: Functional bowel disease and functional abdominal pain. Gastroenterol Int 1992, 5:75-91.
2. Osler W: Diseases of the digestive system. In The Principles and Practice of Medicine, edn 4. London: Henry Kimpton; 1901:544-545.
3. Farthing MJG: Irritable bowel, irritable body, irritable brain? BMJ 1995, 310:171-175.
4. Whorwell PJ, McCallum M, Creed FH, et al.: Non-colonic features of irritable bowel syndrome. Gut 1986, 27:37-40.
5. Drossmann DA, Creed FH, Olden KW, et al.: Psychosocial aspects of the functional gastrointestinal disorders. Gut 1999, 45(Suppl II): II25-II30.
6. Manning AP, Thompson WG, Heaton KW, Morris AF: Towards positive diagnosis of the irritable bowel. BMJ 1978, 11:653-654.
7. Thompson WG, Longstreth GF, Drossman DA, et al.: Functional bowel disorders and functional abdominal pain. Gut 1999, 45(Suppl II): II43-II47.
8. Cash BD, Chey WD: Review article: Irritable bowel syndrome - an evidence-based approach to diagnosis. Aliment Pharmacol Ther 2004, 19:1235-1245.
9. Spiller R: Disturbances in large bowel motility. Baillieres Clin Gastroenterol 1999, 13:397-413.
10. Maxton DG, Morris JA, Whorwell PJ: Ranking of symptoms by patients with the irritable bowel syndrome. BMJ 1989, 299:1138.
11. Talley NJ: Irritable bowel syndrome: definition, diagnosis and epidemiology. Baillieres Clin Gastroenterol 1999, 13:371-384.
12. Talley NJ, Phillips SF, Bruce B, et al.: Multisystem complaints in patients with the irritable bowel syndrome and functional dyspepsia. Eur J Gastroenterol Hepatol 1991, 3:71-77.
13. Schmulson M, Lee OY, Naliboff B, Mayer EA: Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol 1999, 94:2929-2935.
14. Vandik PO, Wilhelmsen I, Ihlebaek C, Farup PG: Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications. Aliment Pharmacol Ther 2004, 20:1195-1203.
15. Cremonini F, Talley NJ: Review article: The overlap between functional dyspepsia and irritable bowel syndrome: a tale of one or two disorders? Aliment Pharmacol Ther 2004, 20(Suppl 7):40-49.
16. Agreus L, Svardsudd N, Nyren O, Tibblin G: Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995, 109:671-680.
17. Mayer EA, Collin SM: Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 2002, 122:2032-2048.
18. Gorard DA, Farthing MJG: Intestinal motor function in irritable bowel syndrome. Dig Dis Sci 1994, 12:72-74.
19. Corsetti M, Cesana B, Bhoori S, Basilisco G: Rectal hyperreactivity to distention in patients with irritable bowel syndrome: role of distention rate. Clin Gastroenterol Hepatol 2004, 2:49-56.
20. Prior A, Maxton DG, Whorwell PJ: Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects. Gut 1990, 31:458-462.
21. Lea R, Houghton LA, Calvert EL, et al.: Gut-focused hypnotherapy normalizes disordered sensitivity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003, 17:635-642.
22. Goldberg PA, Kamm MA, Setti-Carraro P, et al.: Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996, 57:478-483.
23. Mayer EA: The neurobiology of stress and gastrointestinal disease. Gut 2000, 47:861-869.
24. Spiller RC: Postinfectious irritable bowel syndrome. Gastroenterology 2003, 124:1662-1672.
25. Spiller RC, Jenkins D, Thornley JP, et al.: Increased rectal mucosal enteroendocrine cells, T-lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804-811.
26. Gaynes BN, Drossman DA: The role of psychosocial factors in irritable bowel syndrome. Baillieres Clin Gastroenterol 1999, 13:437-452.
27. Creed F, Guthrie E: Psychological factors in the irritable bowel syndrome. Gut 1987, 28:1307-1318.
28. Ford MJ, Miller PM, Eastwood J, Eastwood MA: Life events, psychiatric illness and the irritable bowel syndrome. Gut 1987, 28:160-165.
29. Lydiard RB, Fossey MD, Marsh W, Ballenger JC: Prevalence of psychiatric disorders in patients with the irritable bowel syndrome. Psychosomatics 1993, 34:229-234.
30. Chadwick VS, Chen W, Shu D, et al.: Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002, 122:1778-1783.
31. Efskind PS, Bernklev T, Vatn MH: A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996, 31:463-468.
32. Jaiwala J, Imperiale TF, Kroenke K: Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000, 133:136-147.
33. Poynard T, Naveau S, Mory B, et al.: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994, 8:499-510.
34. Poynard T, Regimbeau C, Benhamou Y: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001, 15:355-361.
35. Whorwell PJ, Prior A, Colgan SM: Hypnotherapy in severe irritable bowel syndrome, further experience. Gut 1987, 28:423-425.
36. Talley NJ, Owen BK, Boyce P, Paterson K: Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996, 91:277-283.
37. Klein KB: Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1977, 95:232-241.
38. Akehurst R, Kaltenthaler E: Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001, 48:272-283.
39. Jackson JL, O'Malley PG, Tomkins G, et al.: Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000, 108:65-72.
40. Gorard DA, Libby GW, Farthing MJG: Effect of a tricyclic anti-depressant on small intestinal motility in health and in diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995, 40:86-95.
41. Gorard DA, Libby GW, Farthing MJG: 5 hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine uptake. Gut 1994, 34:496-500.
42. Farthing MJG: Irritable bowel syndrome: new drugs and therapeutic horizons. In Basic Mechanisms of Digestive Diseases: The Rationale for Clinical Management and Prevention. Edited by Farthing MJG, Malfertheiner P. Paris: John Libbey Eurotext; 2002:59-73.
43. Farthing MJG: New drugs in the management of the irritable bowel syndrome. Drugs 1998, 56:11-21.
44. Farthing MJG: Irritable bowel syndrome: new pharmaceutical approaches to treatment. Baillieres Clin Gastroenterol 1999, 13:461-471.
45. Bearcroft CP, Perrett D, Farthing MJG: Post-prandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome. Gut 1998, 42:42-46.
46. Houghton LA, Atkinson W, Whitaker P, et al.: Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003, 52:1799-800.
47. Bose M, Nickols C, Feakins R, et al.: A comparison of 5-hydroxytryptamine staining in enterochromaffin cells between irritable bowel syndrome and other gastrointestinal disorders. Gut 2000, 47(Suppl III):A 210.
48. Camilleri M, Nortcutt AR, Kong S, et al.: Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000, 355:1035-1040.
49. Camilleri M, Chey WY, Mayer LA, et al.: A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001, 161:1733-1740.
50. Rabasseda X, Leeson P, Silvestre J, Castaner J: Cilansetron: drugs of the future 1999, 24:475-482.
51. Holzer P, Painsipp E, Weber E, et al.: 5-HT3 receptor antagonists, alosetron and cilansetron impair mesenteric blood flow in rats. Gastroenterology 2003, 124(suppl 1):A148-A149.
52. Pimental M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503-3506.
53. Niedzielin K: A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001, 13:1143-1147.
54. O'Mahoney L, McCarthy J, Kelly P, et al.: Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551.
55. Hamilton-Miller JMT: Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microbial Ecol Health Dis 2001, 3:212-216.
56. Dunlop SP, Jenkins D, Neal KR, et al.: Randomized, double-blind placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003, 18:77-84.
57. Bensoussan A, Talley NJ, Hing M, et al.: Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998, 280:1585-1589.
58. Sung JJ, Leung WK, Ching JY, et al.: Agreements among traditional Chinese medicine practitioners in the diagnosis and treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004, 20:1205-1210.
59. Madisch A, Holtmann G, Plein K, Hotz J: Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled multi-centre trial. Aliment Pharmacol Ther 2004, 19:271-279.
60. Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ III: Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992, 136:165-177.
61. El-Serag HB, Pilgrim P, Schoenfeld: Systematic review: Natural history of irritable bowel syndrome. Aliment Pharmacol Ther 2004, 19:861-870.